

Index

α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 41, 42, 194
 2D electrophoresis, 260
 2-Mercaptoethylamine (2 MEA), 141
 3-Dimensional (3D) crystallographic studies, 28, 213
 4-Hydroxynonenal (HNE), 160
 5-Hydroxy tryptamine (5-HT)\t see Serotonin, 112
 8-Oxoguanine (8-oxoG), 22, 25
 8-Oxoguanine DNA-glycosylase 1 (OGG1), 25

A

Acetylcholinesterase (AChE) inhibitors, 60, 143, 171, 276
 Acetyl-l-carnitine, 183, 185, 186
 ACTH, 195
 ADHD, 273
 Adipogenesis, 153
 Adrenal cortex, 192, 195
 Adult, 9, 23, 25, 29, 68, 69, 80, 86, 89, 150, 178, 179, 210, 245, 272
 Age, 3, 4, 7, 8, 81–83, 103, 115, 117, 119, 120, 142, 148, 151, 180, 204, 240, 262
 Age-associated cognitive decline (AACD), 273, 274, 284
 Aging, 7, 8, 43, 80, 101, 103, 115, 117, 118, 121, 148, 150, 159, 180, 184, 185, 240, 254, 272, 275
 Aluminum, 132, 138
 Alzheimer's Association, 273
 Alzheimer's disease (AD), 2, 39, 40, 80, 103, 138, 148, 160, 168, 170, 204, 220, 230, 242, 254, 273, 274
 dementia, 68, 117, 240
 forms of, 50, 60, 68–70, 72–75
 familial (FAD), 50, 60, 68, 74

 LEARn (LAD), 68–70, 72, 73, 75
 sporadic (SAD), 50, 60, 74
 in animal models, 257, 260
 lipofuscin, 134
 oxidative stress, 133, 241
 treatment of, 60, 162, 163, 170, 171, 276
 Amyloid beta (A α) peptide, in AD pathology, 240
 Amyloid beta (A β) peptide, in AD pathology, 54, 103, 171
 reduction in ATP generation, 54
 reduction in cytochrome c oxidase activity, 54
 Amyloid precursor protein, 11, 50, 68, 103
 Amyotrophic lateral sclerosis (ALS), 178, 257
 Anti cancer therapy, 150
 Antioxidant, 4, 5, 10, 80, 121–123, 134, 141–143, 148, 149, 151, 164–166, 182, 183, 186, 243, 244
 Antioxidant responsive element (ARE), 182
 Anxiety, 7, 82, 85, 90, 163, 168, 195, 197
 Aplysia californica, 223, 230
 Apoptosis, 5, 52, 59, 101, 105, 123, 142, 161, 181, 184, 185, 207, 243, 244, 247
 Arch-back nursing (ABN), 195, 196
 Astrocytes, 20, 101, 180, 211, 242, 243
 Atherosclerosis, 148, 149
 Autoimmune diseases, 82
 Autoimmune diseases\t see also Autoimmune disorders, 82
 Autoimmune disorders, 85, 90
 Autophagosomes, 60, 133

B

Bacopa monniera, 276
 Bacopa monnieri, 143
 Base excision repair, 20, 26–29, 31, 32
 Batten disease, 134
 BDNF, 7, 38–44, 260

- BER pathway, 26–29, 31, 32
- Bipolar disorder, 73, 220
- Blood-brain barrier (BBB), 3, 21, 121, 139, 257, 259
- Brain, 11, 142, 243
 - DNA damage, 21–24, 26, 28
 - base damage, 21, 22, 24, 26
 - DNA–DNA crosslinks, 21
 - DNA–protein crosslinks, 22, 23
 - double strand breaks (DSBs), 21, 22, 24
 - single-strand breaks (SSBs), 21, 22, 28
- Brain aging
 - anatomical changes, 2, 3
 - chemical changes, 4
 - factors accelerating, 9, 254, 261
 - hypertension, 9
 - oxidative stress, 254, 261
 - stress and depression, 9
 - functional changes, 7, 8
 - attention, 8
 - decision making, 8
 - episodic memory, 8
 - sleep, 8
 - working memory, 8
 - molecular changes, 3, 5
 - epigenetic factors, 3, 5
 - genetic factors, 3, 5
 - neurochemical, 3
 - therapeutic interventions in, 11
 - transition of, 10, 11
 - gene mutations, 11
 - neurodegenerative diseases \t
 - see Alzheimer's disease and Parkinson's disease, 10
 - neuroprotective mechanisms, 10
 - neurorestorative mechanisms, 10
- Brain inflammation, 277
- Brain ischemia, 103, 162, 211
- Butylated hydroxytoluene (BHT), 141
- C**
 - Caenorhabditis elegans, 51, 220, 221
 - Caffeine, 166, 167
 - Calcineurin, 151
 - Calcium dysregulation, 59, 242
 - Calcium homeostasis,
 - alteration of, 5, 181
 - dysregulation in, 180
 - loss of, 242
 - Calcium influx, 180, 196
 - CALERIE, 153
 - Calmodulin kinase II (CaMKII),
 - phosphorylation of, 114
 - Camellia sinensis (tea), 166, 275
 - cAMP, 113, 207, 208, 230
 - cAMP system, animal models of memory, 230
 - Canadian Study of Health and Aging, 258
 - Cancer, 82, 85, 100–102, 119, 120, 122, 123, 125, 148, 160, 166
 - Carbohydrates, 151, 258, 270
 - Cardiovascular disease, 85, 90, 122, 150, 153, 166, 268
 - Carotinoids, 241
 - Cell proliferation, 102, 259
 - Cellular bioenergetics, 180, 185
 - Cellular homeodynamics, 82
 - Cellular homeostasis, 20
 - Central nervous system (CNS)
 - antioxidant defense system, 277
 - biological clock, 111
 - cognitive decline, 139
 - cytokine production, 212
 - disorders in, 285
 - effects of hypoxia, 179
 - glial cells, 180
 - microglial cells activation, 165
 - neurons, 180
 - oxidative damage, 162, 275
 - structure of, 80
 - therapeutics effect in, 269
 - treatment of CNS diseases, 173
 - Cerebrospinal fluid (CSF), 86, 89, 113, 240
 - Choline acetyltransferase (ChAT), 260
 - Chronic fatigue syndrome, 273
 - Circadian rhythm sleep disorders (CRSD), 115
 - Circadian rhythms, 114, 115, 120, 121, 124, 125
 - CLOCK\
 - BMAL1 heterodimer complex, 114
 - Coffea spp.
 - C. arabica L., 166
 - C. canephora L., 166
 - Cognition, 7, 8, 50, 60, 68, 80, 82, 84, 89, 205, 206, 213, 230, 253, 256, 257, 262, 271, 273, 275, 277, 285
 - Cognition enhancement, 271, 274–276
 - Cognitive enhancers, 271, 275, 276, 281
 - Cognitive functions, 3, 11, 148, 178, 179, 204, 219, 220, 230, 232, 234, 240, 254, 255, 269, 271
 - Cognitive impairment, 83, 167, 184, 186, 197, 240, 258, 273, 274
 - Cognitive tests, 149, 282, 283

Co-localization, 54, 172
Complementary DNAs (cDNAs), 38, 96, 102
Corticosteroids, 193, 194, 196
C-reactive protein, 154, 242
CREB, 113, 117, 206–208, 230, 232
CREB phosphorylation, 207, 210, 230
CREM, 230
CSRDs, 122
Curcuma longa L., 164, 275
Curcuminoids, 164
Cybrids, 53
Cyclooxygenase (COX)-2, 164, 181
Cytokines
 interleukin-1 (IL-1), 99, 212
 interleukin-1 (1), 242
 interleukin-10, 212
 interleukin-18 (IL-18), 184
 interleukin-1 β (1 β), 164, 184
 interleukin-6 (IL-6), 153, 212, 242
D
Dementia, 4, 50, 68, 89, 117, 123, 138, 143,
 148, 162, 163, 165, 168, 178, 204,
 210, 220, 226, 240, 243, 254, 258,
 271, 273, 275, 277, 285
Dentate gyrus (DG), 5, 255
Depression, 117, 122, 192, 195, 226, 255
Diabetes, 148–150
 in animal model, 124
 type 2 diabetes, 124, 245
Diet, 2, 11, 15, 70, 72, 141, 153, 154,
 243–245, 254, 256, 258, 275
Dietary restriction (DR), 11, 148, 150
Dietary supplements, 254, 257
Diffusion tensor imaging (DTI), 255
Difluorothioacetylfluoride (DFTAL), 104
DNA, 20–22, 24, 26, 53, 68, 72, 73, 75, 240,
 256
DNA damage, 2, 20–22, 24–26, 32, 81, 122,
 181, 182, 247, 260
DNA methylation, 72–75
DNA migration, 23–25
DNA polymerase β , 22, 27
DNA relaxation, 24, 25
DNA repair systems, 20, 32
Docosahexaenoic acid (DHA), 244, 284, 285
Dopamine, 4, 244
 metabolism of, 161
DR/CR, 150
Drosophila, 51, 220, 230
DSM-IV, 273

E
Eicosapentaenoic acid (EPA), 244, 285
Electroencephalography, 271
Electron microscopy, 60, 137, 141, 143, 246
Electron transport chain (ETC), 82, 122, 181,
 241
Environment, 2, 8, 21, 70, 72
Environmental enrichment, 80, 84, 86, 87, 89,
 148, 149, 197
Epidermal growth factor (EGF), 38
Epigallocatechin-3-gallate (EGCG), 167
Epigenetics, 5, 74
Epigenome, 74
Epilepsy, 232, 273
Epileptic seizures, treatment of, 225
Escherichia coli Hsp70 chaperone, 97
Estrogen, 4, 11, 204–207, 210–212
Estrogen replacement therapy, 205, 212
Estrogen response element (ERE), 206
Estrogen therapy, 166, 211, 214
Extracellular signal-regulated kinases (ERKs),
 133
F
Fear conditioning, 193, 196
Fibroblast growth factor (FGF), 38
 FGF-1, 99, 104, 149
Fibromyalgia, 273
Flavonoids, 162, 165, 243, 244, 247, 258, 259,
 270, 284
Fluorescence in situ hybridization, 96
Fluorescent fluorophores, 134
Folic acid, 285
Framingham Study, 165
Functional MRI (fMRI), 3, 234, 271
G
Gamma (γ)-amino butyric acid (GABA), 113,
 169
Gene regulation, 4, 70, 72, 223
Gene transcription, 183, 206, 223, 230
Genes, 5, 7, 11, 50, 68, 70, 73, 81, 114, 149,
 226
Genetically modified mice, 220, 227, 230, 232
Ginkgo biloba L., 162, 277
Glial fibrillary acid proteins, 242
Glucocorticoid receptor (GR), 192, 194, 197
Gluconeogenesis, 153
Glucose deprivation, 96, 103
Glucose homeostasis, 153
Glutathione (GSH), 81, 82, 121–123, 241, 257
Good Agricultural Process (GAP), 284
Good Clinical Practice (GCP), 284

Good Laboratory Practice (GLP), 284
 Grape seed proanthocyanidin extract (GSPE)
 effectiveness of, 260
 in animal model, 260
 neuroprotective ability of, 260

H

Herbal medicines, 162, 268, 269, 277
 Hippocampal neurogenesis, 85, 149
 Hippocampus, 5, 7, 9, 40, 41, 43, 50, 80, 81,
 83–85, 89, 103, 149, 161, 168, 169,
 171, 192, 206, 224, 260, 261
 HIV, 85
 Homocysteine (Hcy), 9, 285
 Hormetins, 162, 165, 183, 241, 270, 275
 Hormones, 2, 4, 11, 113, 119, 141, 192–194,
 196–198, 204, 206
 Hyoscyamus niger L., 269
 Hypertension, 9, 150, 273
 Hypothalamic-pituitary-adrenal (HPA) axis,
 dysregulation of, 83, 85, 192, 195, 196
 Hypoxia, 10, 178–182, 184, 186
 Hypoxia inducible factor (HIF), 186

I

ICER, 113, 220, 227, 230, 231, 233
 Immunoblotting techniques, 54
 Immunoscreening, 96
 Immunosenescence, 83
 Inflammation, 5, 9, 70, 119, 120, 148, 161,
 164, 240, 242, 243, 254, 275, 277
 Inflammatory, 51, 58, 73, 205, 276
 Insomnia, 8, 117, 123, 124, 168
 Insulin, 4, 153, 154
 Insulin degrading enzyme (IDE), 69
 Insulin-like growth factors (IGFs), 4

L

Latency, 74, 75, 210, 260
 Learning, 9, 40, 80, 84, 89, 102, 141, 149,
 169, 192, 193, 195, 205, 211, 220,
 225
 Levodopa (l-DOPA), 161
 Lifestyle interventions, 148
 Lipid, 151
 Lipid peroxidation, 81, 104, 121, 122, 135,
 138, 140, 142, 143, 160, 165, 168,
 181, 182, 241, 245, 258–260
 Lipids, 58, 133, 138, 181, 240, 241, 255, 257,
 258, 260
 Lipofuscin, 81, 132, 134, 137, 138, 141
 Lipofuscin inhibitors, 141
 Lipofuscinogenesis, 138, 140

Lipoxygenase (LOX), 164
 Longevity extension, 80, 83, 86, 87, 89, 149,
 162
 Long-term depression (LTD), 39–41, 225, 226
 Long-term potentiation (LTP), 40, 41, 43, 44,
 225, 226, 257
 Low density lipoprotein (LDL), 124, 244, 259
 LSPC, 260, 261
 LTD\† see Long-term depression, 39
 LTP\† see Long-term potentiation, 40

M

Macroautophagy, 133
 Magnetic resonance imaging (MRI), 3, 86,
 255
 Malondialdehyde (MDA), 160, 260
 MAPK pathways, 207
 Mass spectrometry, 54, 260
 Melatonin, 4, 11, 60, 112–114, 118, 119,
 121–124, 243, 247
 Melatonin therapy, 122
 Memantine, 161, 273, 276, 277
 Memory
 age-related impairment, 82
 classification of, 2, 7, 40, 43, 222–224,
 226, 271
 declarative memory, 224, 226, 271
 long-term memory (LTM), 2, 7, 40, 43,
 222, 223
 non-declarative memory, 224, 226
 short-term memory (STM), 40, 43,
 222, 223
 during sleeping, 8
 episodic memory, 8
 hormones effects, 193
 impairments, 272
 semantic memory, 8
 working memory, 8
 Memory-enhancing drugs
 development of, 220, 233
 Mercuric chloride, 104
 Metal dysregulation, 58
 Metals, 58, 70, 132, 161, 164
 Michael adducts, 134
 Microarray, 4, 74
 Mineralocorticoid receptor (MR), 192, 193,
 197
 Mitochondrial, 4, 5, 21, 51, 52, 54, 185, 186,
 241, 256
 Mitochondrial dysfunction,
 AD brains, 51, 54, 55, 58–60
 apoptosis, 58, 59
 A β 42 accumulation of, 58, 60

- cross talk, 60
- in vitro studies, 55
- mitochondrial depolarization, 60
- physiology, 51
- treatment, 60
- brain aging, 2, 82, 121, 122, 165, 186, 240, 242
- in animal model, 165
- ROS production, 121
- Mitogen-activated protein (MAP) kinases (MAPK), 39, 167, 207
- Mongolian gerbils, 165
- Mortalin, 96–105
- Multiple sclerosis, 273
- Mutations, 11, 20, 21, 50, 68, 99, 104, 121, 134, 180
- N**
- NADPH-d, 168, 169, 171–173
- Narcolepsy, 273
- National Institute on Aging (NIA), 273
- Natural medicinal products, 268
- Necrosis, 52, 59, 102, 184
- Nerve growth factor (NGF), 38, 39, 149
- Neurobiology, 38, 80, 101
- Neurodegeneration, 15, 60, 85, 102, 104, 118, 123, 148, 163, 169, 186, 204, 211, 213
- Neurodegenerative diseases \t see Alzheimer's disease and Parkinson's disease, 10
- Neurodegenerative disorders, 2, 52, 68, 73, 79, 85, 105, 117, 138, 141, 142, 150, 167, 181, 185, 186, 205, 212, 255
- Neuroendocrine-immune system, 82
- Neurofibrillary tangles, 50, 161, 204, 240
- Neuroimaging, 2
- Neuro-immune-endocrine communication, 82, 84
- Neuroinflammation, 83, 184, 242
- Neurolipofuscin, 141
- Neuronal DNA, 25, 26
- Neuronal nitric oxide synthase (nNOS), 168
- Neuronal survival, 5, 38, 39, 168, 181, 207, 208, 210
- Neuroprotection, 11, 117, 150, 162, 166, 169, 183, 207, 208, 213, 260, 276
- Neurospora crassa, 142
- Neurotransmitter, 2, 4, 11, 117, 118, 161, 169, 170, 173, 193, 275, 276
- Neurotrophin, 38–40, 186
- discovery of, 38
- Neurotrophin BDNF, 149
- Nitric oxide (NO)
- metabolism of, 168
- neurotoxic effects of, 172
- Nitric oxide synthase (NOS), 242
- N-methyl-d-aspartate (NMDA) receptors, 39, 41, 56, 161, 181, 212
- Non-steroidal anti-inflammatory drugs (NSADs), 60, 164
- Nootropics, 256
- Noradrenaline, 193, 194, 197
- Norepinephrine (NE), 113, 118
- Nrf-2, 182, 184, 186
- Nuclear factor-kappa beta (NF-kB), 260
- Nutrition, 150, 256, 271, 272
- O**
- Obesity, 4, 150, 268
- Old, 8, 86, 87
- Oligomeric proanthocyanidins (OPCs), 259
- Osteoporosis, 124
- Oxidative stress, 69, 80, 181, 182, 184–186, 207, 240–243, 246, 247, 254, 255, 261, 276
- P**
- Papaver somniferum L., 269
- Parkin, 11, 105
- Parkinson's disease, 2, 68, 73, 117, 168, 220, 242, 254, 257
- PCD \t see Programmed cell death, 59
- Permeability transition pore (PTP), 181
- PET, 233
- Pharmacodynamics, 124
- Pharmacokinetics, 124
- Physical activity, 85, 148, 149, 256
- Phytochemicals, 162, 165, 173, 183, 241, 269, 270, 275
- PKA, 113, 207, 230
- Plasticity-related proteins (PRPs), 41
- Polymorphism, 38, 43, 69
- Polyunsaturated fatty acids, 81, 122, 160
- Post-translational modifications, 50, 114, 181
- Post-traumatic stress disorder (PTSD), 192, 232
- Presenilin 1 (PS1), 50, 69
- Presenilin 2 (PS2), 50
- Proanthocyanidin, 166, 259
- Procyanolic oligomers (PCOs), 259
- Progesterone, 4
- Programmed cell death, 52, 58, 59
- Proliferating cell nuclear antigen (PCNA), 28
- Protein kinase B, 206

Protein oxidation, 81, 143, 180, 182, 258, 260
 Proteins, 10, 28, 38, 40, 74, 81, 96, 151, 154, 258, 270
 Psychologists, 222
 Psychopathology, 195
 Psychopharmacology, 269, 277, 282
 Pycnogenol, 275

Q

Quantitative RT-PCR (qRT-PCR), 53, 54
 Quercetin, 150, 162, 165, 166

R

RAGE, 56, 242
 Reactive nitrogen species (RNS), 121, 255
 Reactive oxygen species (ROS), 2, 21, 52, 81, 121–123, 135, 143, 160, 181, 241, 255
 Retinohypothalamic tract (RHT), 112, 113
 RNA, 40, 42, 50, 101, 102, 104, 113, 114, 118, 125

S

Schiff-base cross-links, 134
 Schizophrenia, 40, 73, 220, 273
 SCN neurons, 112, 113, 115, 119
 Selenium, 285
 Septic shock, 123
 SERM, 213
 Serotonin, 4, 112, 117, 119, 169, 170, 244
 Serum deprivation, 207
 Sexual dimorphism, 5
 Sexual dysfunction, 122
 Sexual hormones
 DHEA, 4
 estrogens, 83, 205
 17 α estradiol (17 α), 205
 estradiol/17(estradiol (E2), 205
 estradiol/17 β estradiol (E2), 83
 estriol (E3), 205
 estrone (E1), 205
 progesterone, 4
 testosterone, 4, 83
 Sick chaperones, 104
 Single nucleotide polymorphism (SNP), 39, 149
 Sirtuins, 125, 149, 150, 153
 Sleep dysregulation, 8
 Sleep dysregulation 't see also Insomnia, 8
 Sodium nitroprusside (SNP), 165
 Spatial learning, 44, 85, 195, 197, 245, 255
 Standardization, 270, 271, 282
 Stress, 9, 169, 196

Stress hyporesponsive period (SHRP), 195
 Stroke, 2, 148, 149, 162, 165, 166, 183, 184, 285
 Suprachiasmatic nucleus, 111
 Synapses, 3, 101, 102, 172, 173, 223, 226, 275
 Synaptic plasticity, 40, 149, 151, 152, 168, 195, 207, 208, 212, 213, 225, 244
 Synaptogenesis, 51, 85, 208

T

T lymphocytes, 83
 Tamoxifen (TAM), 213
 TCA cycle, 53, 55, 58
 Telomeres shortening, 9, 256
 Tetrafluoroethylcysteine (TFEC), 104
 Therapeutics, 4, 101, 125, 173, 232, 234, 269
 Thioflavin T (ThT) fluorescence spectroscopy, 245
 Thyroid stimulating hormone (TSH), 115
 Thyroxine, 4
 Traditional Chinese Medicine (TCM), 162, 163, 268, 269
 Training, 40, 282
 Trans Golgi network, 56
 Traumatic brain injuries, 2
 TrkB, 39–43
 Tumor necrosis factor-(TNF-), 242
 Tumor necrosis factor- α (TNF- α), 124, 212
 TUNEL assay, 60, 208

V

Ventriculomegaly, 3, 9
 Vitamin B12, 243, 256, 284, 285
 Vitamin B6, 243, 284, 285
 Vitamin C, 123, 241, 258, 285
 Vitamin E, 60, 123, 141, 142, 241, 243, 256–258, 262, 285

W

Walnuts, 240, 243–247
 Werner syndrome protein helicase (WRN), 28
 Western blot, 31
 Withania somnifera, 167, 168
 World Health Organization (WHO), 79, 160

Y

Young, 29, 30, 103, 115, 137, 151, 211, 272, 281, 283
 α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 81



<http://www.springer.com/978-94-007-5236-8>

Brain Aging and Therapeutic Interventions

Thakur, M.K.; Rattan, S.I.S. (Eds.)

2012, XII, 296 p., Hardcover

ISBN: 978-94-007-5236-8